OBJECTIVE: To identify the cause of childhood onset involuntary paroxysmal choreiform and dystonic movements in 2 unrelated sporadic cases and to investigate the functional effect of missense mutations in adenylyl cyclase 5 (ADCY5) in sporadic and inherited cases of autosomal dominant familial dyskinesia with facial myokymia (FDFM). METHODS: Whole exome sequencing was performed on 2 parent-child trios. The effect of mutations in ADCY5 was studied by measurement of cyclic adenosine monophosphate (cAMP) accumulation under stimulatory and inhibitory conditions. RESULTS: The same de novo mutation (c.1252C>T, p.R418W) in ADCY5 was found in both studied cases. An inherited missense mutation (c.2176G>A, p.A726T) in ADCY5 was previously reported in a family with FDFM. The significant phenotypic overlap with FDFM was recognized in both cases only after discovery of the molecular link. The inherited mutation in the FDFM family and the recurrent de novo mutation affect residues in different protein domains, the first cytoplasmic domain and the first membrane-spanning domain, respectively. Functional studies revealed a statistically significant increase in β-receptor agonist-stimulated intracellular cAMP consistent with an increase in adenylyl cyclase activity for both mutants relative to wild-type protein, indicative of a gain-of-function effect. INTERPRETATION: FDFM is likely caused by gain-of-function mutations in different domains of ADCY5-the first definitive link between adenylyl cyclase mutation and human disease. We have illustrated the power of hypothesis-free exome sequencing in establishing diagnoses in rare disorders with complex and variable phenotype. Mutations in ADCY5 should be considered in patients with undiagnosed complex movement disorders even in the absence of a family history.
OBJECTIVE: To identify the cause of childhood onset involuntary paroxysmal choreiform and dystonic movements in 2 unrelated sporadic cases and to investigate the functional effect of missense mutations in adenylyl cyclase 5 (ADCY5) in sporadic and inherited cases of autosomal dominant familial dyskinesia with facial myokymia (FDFM). METHODS: Whole exome sequencing was performed on 2 parent-child trios. The effect of mutations in ADCY5 was studied by measurement of cyclic adenosine monophosphate (cAMP) accumulation under stimulatory and inhibitory conditions. RESULTS: The same de novo mutation (c.1252C>T, p.R418W) in ADCY5 was found in both studied cases. An inherited missense mutation (c.2176G>A, p.A726T) in ADCY5 was previously reported in a family with FDFM. The significant phenotypic overlap with FDFM was recognized in both cases only after discovery of the molecular link. The inherited mutation in the FDFM family and the recurrent de novo mutation affect residues in different protein domains, the first cytoplasmic domain and the first membrane-spanning domain, respectively. Functional studies revealed a statistically significant increase in β-receptor agonist-stimulated intracellular cAMP consistent with an increase in adenylyl cyclase activity for both mutants relative to wild-type protein, indicative of a gain-of-function effect. INTERPRETATION: FDFM is likely caused by gain-of-function mutations in different domains of ADCY5-the first definitive link between adenylyl cyclase mutation and human disease. We have illustrated the power of hypothesis-free exome sequencing in establishing diagnoses in rare disorders with complex and variable phenotype. Mutations in ADCY5 should be considered in patients with undiagnosed complex movement disorders even in the absence of a family history.
Authors: Jeffrey A Bailey; Zhiping Gu; Royden A Clark; Knut Reinert; Rhea V Samonte; Stuart Schwartz; Mark D Adams; Eugene W Myers; Peter W Li; Evan E Eichler Journal: Science Date: 2002-08-09 Impact factor: 47.728
Authors: Dong-Hui Chen; Alipi Naydenov; Jacqueline L Blankman; Heather C Mefford; Marie Davis; Youngmee Sul; A Samuel Barloon; Emily Bonkowski; John Wolff; Mark Matsushita; Corrine Smith; Benjamin F Cravatt; Ken Mackie; Wendy H Raskind; Nephi Stella; Thomas D Bird Journal: Hum Mutat Date: 2013-10-02 Impact factor: 4.878
Authors: Esther A R Nibbeling; Cathérine C S Delnooz; Tom J de Koning; Richard J Sinke; Hyder A Jinnah; Marina A J Tijssen; Dineke S Verbeek Journal: Neurosci Biobehav Rev Date: 2017-01-28 Impact factor: 8.989
Authors: Christine P Diggle; Stacey J Sukoff Rizzo; Michael Popiolek; Reetta Hinttala; Jan-Philip Schülke; Manju A Kurian; Ian M Carr; Alexander F Markham; David T Bonthron; Christopher Watson; Saghira Malik Sharif; Veronica Reinhart; Larry C James; Michelle A Vanase-Frawley; Erik Charych; Melanie Allen; John Harms; Christopher J Schmidt; Joanne Ng; Karen Pysden; Christine Strick; Päivi Vieira; Katariina Mankinen; Hannaleena Kokkonen; Matti Kallioinen; Raija Sormunen; Juha O Rinne; Jarkko Johansson; Kati Alakurtti; Laura Huilaja; Tiina Hurskainen; Kaisa Tasanen; Eija Anttila; Tiago Reis Marques; Oliver Howes; Marius Politis; Somayyeh Fahiminiya; Khanh Q Nguyen; Jacek Majewski; Johanna Uusimaa; Eamonn Sheridan; Nicholas J Brandon Journal: Am J Hum Genet Date: 2016-04-07 Impact factor: 11.025
Authors: Marissa Dean; Ludwine Messiaen; Gregory M Cooper; Michelle D Amaral; Salman Rashid; Bruce R Korf; David G Standaert Journal: Neurology Date: 2019-09-10 Impact factor: 9.910
Authors: Carmen W Dessauer; Val J Watts; Rennolds S Ostrom; Marco Conti; Stefan Dove; Roland Seifert Journal: Pharmacol Rev Date: 2017-04 Impact factor: 25.468
Authors: Ali Torkamani; Kevin Bersell; Benjamin S Jorge; Robert L Bjork; Jennifer R Friedman; Cinnamon S Bloss; Julie Cohen; Siddharth Gupta; Sakkubai Naidu; Carlos G Vanoye; Alfred L George; Jennifer A Kearney Journal: Ann Neurol Date: 2014-09-19 Impact factor: 10.422
Authors: Wendy H Raskind; Jennifer R Friedman; Emmanuel Roze; Aurélie Méneret; Dong-Hui Chen; Thomas D Bird Journal: Mov Disord Date: 2016-12-09 Impact factor: 10.338